

Caltech/MIT Enterprise Forum
January 20, 2004
MEDICAL DEVICES: The Power of Small

KEYNOTE SPEAKER

Bill Van Antwerp
Vice President, Chief Scientific Officer
Medtronic Minimed

Bill Van Antwerp was the first chemist and one of the first scientists to join Minimed in 1985, after several years of successful consulting for them. The original product goal was to develop stable insulin for implantable pumps. The pumps went into clinical trials in 1992. While at Minimed, Bill was involved in developing the first FDA approved continuous glucose monitor and in pioneering continuous protein drug delivery for a variety of disease states. This work has led to successful NDA labeling of one drug and several drugs are now in late stage clinical trials.

During this time, Bill developed a core group of protein analytical science and protein biophysics at Minimed. Since being acquired by Medtronic in 2001, Bill has been elected to the Bakken Society, Medtronic's highest technical achievement and has been active in corporate strategic development of biotech and drug delivery therapies.

Bill has a B.S. from Rutgers University and an M.S. from SUNY.

ENTREPRENEURS

Richard Piazza
President
TheraFuse, Inc.

C. Richard Piazza is a senior executive with extensive profit and loss general management responsibility. He has a demonstrated record of building and managing teams, increasing revenues, raising profitability, and capturing increased market share. He is skilled in product diversification, product development and business growth through joint ventures, licensing and partnerships.

Mr. Piazza is the President and Chief Executive Officer of TheraFuse, Inc., a maker of wearable insulin infusion pumps. Using microelectromechanical (MEMS) technology, TheraFuse has developed a medication-specific drug delivery system for insulin that provides superior therapy in a user-friendly form at a competitive price. The TheraFusor(TM) is approximately the size and thickness of a silver dollar and will be held in place on the skin by an adhesive. A disposable component contains insulin and microneedles. Snapping into that is a reusable unit that contains the logic, metering and communication circuits. By use of a proprietary metering system, the TheraFusor will automatically deliver the correct insulin dose.

Mr. Piazza served as President of Maxia Pharmaceuticals, Inc., 2001-2002. Maxia was a late stage biotechnology company with applications in cervical dysplasia, Type 2 Diabetes, cancer and inflammatory diseases. Mr. Piazza served as President of VitaGen, Inc., from 1994-2000. VitaGen developed an extracorporeal liver assist device (ELAD™). The product, while employing an engineered human liver cell, is actually a hybrid device consisting of a specialized blood pumping system (Class III PMAA) and a biologically active (human hepatocytes) single patient use cartridge (Biological BLA). Mr. Piazza also served as President of Marquest Medical Products, Inc., 1992-1993, Bioelectron, Inc., 1987-1989; and Radius Health System Services & Supplies, 1984-1987.

Amit Rikhy
Chief Financial Officer
Anamed, Inc.

Mr. Rikhy is the CFO and EVP of Finance of Anamed, Inc. Anamed is a biomedical technology company that develops implantable products that correct and maintain vision, and are made from its proprietary Nutrapore® micro-porous hydrogel material. The Company is a privately held corporation, founded in Southern California in 1996.

Mr. Rikhy brings over 15 years of domestic and international experience in corporate finance, strategy, mergers and acquisitions, and business development. Most recently, Mr. Rikhy was providing M&A and corporate finance advisory services to clients in the life sciences and biotechnology sector. Prior to this, he was CFO and SVP Strategy and Acting CFO and VP Corporate Development for two emerging telecommunications companies, where Mr. Rikhy was responsible for all aspects of these companies' finance departments, including financial development activities, reporting, budgeting, and analysis. Mr. Rikhy led the financial and strategic structuring of these two companies, enabling them to dramatically improve their balance sheets, increase revenues and reduce costs. He has worked with a number of institutional investors and has been responsible for successfully managing and executing acquisitions and projects worth approximately \$1 billion.

Mr. Rikhy holds a Bachelor's degree in Economics from the University of Virginia, where he was an Echols Scholar and a MBA with a concentration in finance from the Johns Hopkins University, where he was the recipient of the Stegman Award for Excellence.

PANELISTS

Dr. Rae Drazin
President
Science Consultants to Industry

Rae Drazin, Ph.D. is President of Science Consultants to Industry (SCI), a consulting firm she founded in 1984. The firm consults to the medical device and pharmaceutical industries in the areas of microbiology, chemistry and toxicology and specializes in the evaluation of drug/device interactions and antimicrobial coatings. Before founding SCI, Dr. Drazin spent 6 years as the Director of Microbiology and Toxicology at several Los Angeles area independent testing laboratories where she developed specialized protocols and established GLP programs. Her background also includes teaching

biology and hematology at California State University, Fullerton and Cal State Dominquez Hills. Prior to teaching, Dr. Drazin held several research post-doctoral positions at UCLA where she studied tumor antigens and human antimicrobial proteins.

Dr. Drazin holds a Ph.D. from UCLA in Microbiology.

Mark Kroll, Ph.D.
Chief Technology Officer
St. Jude Medical, Incorporated

Dr. Kroll is the Senior Vice President and Chief Technology Officer, St. Jude Medical Inc., Cardiac Rhythm Management Division. He began as VP of Tachycardia Business Unit and held various VP level positions within St. Jude since 1995. <http://www.sjm.com> Previous to that, Dr. Kroll held various positions at Angeion Corp. ('91-'95) most recently VP of research and product planning.

Dr. Kroll holds a B.S. Mathematics and M.S. and Ph.D. in Electrical Engineering from the University of Minnesota, and an M.B.A. from the University of St. Thomas.

Dr. Kroll holds 142 issued U.S. patents and is honored by the U.S. Patent and Trademark Office as a prolific inventor, was awarded "Fellow" recognition by the American College of Cardiology (FACC), and co-author of **Implantable Cardioverter Defibrillator Therapy** published by Kluwer of Boston. Dr. Kroll is listed in Who's Who In Science And Engineering since 1992. He has authored over 75 papers, invited presentations, book chapters, and abstracts.

Dr. Kroll was a co-founder of SurVivaLink which is now the major part of Cardiac Science (DFIB). His is a director of Harbinger Medical, Inc (Cardiac Diagnostic), Guidance Interactive, Inc (Diabetes Monitoring), Arrowhead Offshore Partners, Ltd (Venture Capital), and OncoStim, Inc (DC Ablation for Cancer).

Dr. Kroll is an annual invited lecturer to the UCLA Anderson School week long "Creativity and Innovation" program, and an invited speaker to the United States Patent and Trademark Office.

Dr. Kroll is of a handful of Non-MDs – and the only practicing EE - to have been granted the FACC honor. He is the top inventor of implantable medical devices in the world; 99% of the ICDs (Implantable Cardioverter Defibrillator) sold have at least one licensed Kroll patent.

Ron Lebel
President
Medical Research Products, Inc.

Ron Lebel is the current President of Medical Research Products, Sylmar, CA The company is engaged in the development of active implantable medical devices. MRP is currently developing an implantable pump for the treatment of pain and an implantable hearing aid. MRP was founded in 2001 by Mr. Lebel and Alfred Mann.

Prior to his involvement with Mr. Mann in medical device development, Mr. Lebel lead research and development efforts in computer hardware and software companies. Mr.

Lebel has 11 years experience in medical devices and 5 years experience in implantable pumps. Mr. Lebel holds a BA in Mathematics, Honors Program, from Boston College.

Alice H. Muntz, Ph.D.
Associate Director of Development
Chief Operating Officer
UCLA Institute for Cell Mimetic Space Exploration

Dr. Alice Muntz is a veteran executive and entrepreneur with over 27 years experience in the computer technology sector. She is the Associated Director of Development and Chief Operating Officer of the Institute for Cell Mimetic Space Exploration (CMISE). She also founded Vizional Technologies in 1999. Under her leadership Vizional has developed the most advanced collaborative commerce platform available today. She has raised more than \$53 million dollars and established key corporate strategic alliance agreements with Fortune 500 companies including Prologis and I2. Prior to founding Vizional, Dr. Muntz held positions at AT&T (Teradata), Hughes and Xerox, where she led efforts in technology and product development and information technology services including data warehousing, touch screen human interfaces, real-time systems, and reengineering services.

Dr. Muntz is a member of several advisory boards including the Industrial Advisory Board of the UCLA Henry Samueli School of Engineering, Raytheon Electronic Systems Commercial Ventures, the Sally Ride Science Camp, and the Supply Chain Council of the Aerospace and Defense Steering Committee.

She is a graduate of the University of Southern California where she earned her M.S. and Ph.D. in Computer Science. She earned her B.E. from National Chiao-Tung University in Taiwan. Dr. Muntz has also completed the Executive Management Program at the Kellogg School of Business and received the Directors Training Award from UCLA.

Alex Suh
Managing Director
California Technology Ventures

Alex Suh is a founding Director with California Technology Ventures, LLC, a Southern California venture capital firm that focuses its investments in early stage companies in the fields of Life Sciences and Information Technology. He is the managing director that invests in Life Sciences as well as Information Technology.

Alex is also a founding Managing Director with J.J. Jacobs Enterprises, LLC, a Pasadena-based venture capital firm where he has been responsible for a portfolio of approximately twenty companies. The types of investments have included enterprise software, Internet MMP 3-D gaming, oncology drug resistance testing, gene sequencing and bio-informatics, commercial printing, real estate, food and beverage, drug delivery and others.

Alex currently serves on the following corporate boards: Oncotech, SurroImmunology, Insert Therapeutics, and SupplyEdge. Other Life Science investments include FeRx, Inc. and Digital Gene Technologies.

Before co-founding Jacobs Enterprises and California Technology Ventures, Alex has founded and sold companies, helped develop the first small business incubator in the San Gabriel Valley, managed several small business lending programs, consulted with nonprofits and cities on economic development projects and taught college in entrepreneurship, business, and management.

MODERATOR

Russ Frandsen
Attorney at Law
Squire, Sanders & Dempsey LLP

Mr. Frandsen is an Attorney at Law at Squire, Sanders & Dempsey LLP. Mr. Frandsen has 24 years experience in business law in Los Angeles. Mr. Frandsen is AV rated by Martindale-Hubbell, the highest rating given. Mr. Frandsen has developed considerable expertise in high technology companies, entrepreneurial businesses and venture capital investing. In this connection, he has handled numerous e-commerce, Internet, and technology start up firms, mergers and acquisitions, federal and state securities law issues, including public and private securities offerings, intellectual property licensing and technology transfers, technology joint ventures, securing and protecting trade secrets and intellectual property and related general business problems. Mr. Frandsen serves as outside general counsel to a number of clients in the high technology field.

Mr. Frandsen attended Duke University School of Law, receiving his Juris Doctorate degree in 1976. He completed his undergraduate studies at Brigham Young University, with a B.A. in University Studies, graduating *Magnum Cum Laude* with High Honors in 1973. Mr. Frandsen majored in Physics and Math at the university before deciding to obtain his degree in University Studies. The University Studies degree consists of concentrated academic study in six fields including mathematics, physics, philosophy, history, German and religion.

PROGRAM PRODUCERS

Susan Prado, Executive Director, Pasadena Bioscience Center

Daniel R. Kimbell, Esq. of Christie, Parker & Hale, LLP

SPONSOR

Christie, Parker & Hale LLP

For more than five decades Christie, Parker & Hale has rigorously protected the discoveries and inventions of its clients, and is the second largest purely IP law firm in southern California. With breadth and depth of expertise, experience, judgment and creativity CP&H attorneys specialize in patents, trademarks, copyrights, trade secrets, unfair competition, plant variety protection, related litigation, and international property rights.

Some of CP&H's most successful clients first became clients while still experimenting in their garages. Working hand-in-hand with them, the firm has obtained their first patent, guided them through their initial developments and watched them achieve market leadership.

Anticipating it's clients' needs, CP&H provides practical, cost-effective advice in: 1) The profitable exploitation of intellectual property, 2) Controlling the costs of creating and protecting intellectual property, 3) Licensing intellectual property, 4) Creating and protecting intellectual property in foreign markets, and 5) Dealing with encroachment on intellectual property rights.